Shots:

• Novartis to receive $355M following the closure of acquisition- which is expected to occur in Q2’21. The acquisition expands existing Alcon’s ophthalmic portfolio and strengthens its footprints in the US
• The companies will initiate a transition period where Novartis will continue to sell Simbrinza and transfer the profit to Alcon. Following the transition period- Alcon expects to manufacture & commercialize Simbrinza in the US while Novartis will retain all rights (Ex-US)
• Additionally- Alcon has launched Systane Hydration MDPF lubricant eye drops and is now available in a multi-dose bottle helps to minimize microbial contamination

  Ref: Business Wire | Image: Novartis